News
HRMY
28.93
-1.03%
-0.30
Weekly Report: what happened at HRMY last week (0415-0419)?
Weekly Report · 3d ago
FHLC: Healthcare Dashboard For April
Seeking Alpha · 04/16 20:24
Weekly Report: what happened at HRMY last week (0408-0412)?
Weekly Report · 04/15 10:16
Harmony Biosciences Price Target Maintained With a $49.00/Share by Cantor Fitzgerald
Dow Jones · 04/12 14:03
Cantor Fitzgerald Reiterates Overweight on Harmony Biosciences, Maintains $49 Price Target
Benzinga · 04/12 13:53
Piper Sandler Remains a Buy on Harmony Biosciences Holdings (HRMY)
TipRanks · 04/12 12:30
Analysts Are Bullish on Top Healthcare Stocks: InMode (INMD), Resmed (RMD)
TipRanks · 04/12 05:50
Harmony Biosciences Price Target Maintained With a $50.00/Share by Needham
Dow Jones · 04/11 17:34
Needham Reiterates Buy on Harmony Biosciences, Maintains $50 Price Target
Benzinga · 04/11 17:24
Harmony inks licensing deal for sleep disorder therapy
Healthcare Harmony inks licensing deal for sleep disorder therapy. TPM-1116 will be targeted at sleep/wake disorders, including narcolepsy. Harmony will acquire exclusive rights to develop, manufacture, and commercialize the therapy in the U.S. And Latin America.
Seeking Alpha · 04/11 16:36
Harmony Biosciences Holdings (HRMY) Gets a Sell from Goldman Sachs
TipRanks · 04/11 14:45
Harmony Biosciences Announces Exclusive Agreement To Develop And Commercialize TPM-1116, A Highly Potent And Selective Oral Orexin-2 Receptor Agonist; Harmony Will Pay Bioprojet An Upfront License Fee Of $25.5M For The Exclusive Right
Harmony Biosciences Holdings, Inc. Announces exclusive licensing agreement with Bioprojet to develop, manufacture and commercialize TPM-1116. The oral orexin-2 receptor agonist will be evaluated for the treatment of narcolepsy and other sleep/wake disorders. The agreement will accelerate the development of a new chemical series of OX2R agonists.
Benzinga · 04/11 12:07
HARMONY BIOSCIENCES HOLDINGS INC - HARMONY WILL PAY A ROYALTY RATE IN MID-TEENS ON SALES OF PRODUCT IN LICENSED TERRITORIES
Reuters · 04/11 12:05
HARMONY BIOSCIENCES HOLDINGS INC - HARMONY IS OBLIGATED TO PAY UP TO $240 MLN UPON ACHIEVEMENT OF SALES-BASED MILESTONES
Reuters · 04/11 12:05
Harmony Biosciences Price Target Maintained With a $50.00/Share by Needham
Dow Jones · 04/09 10:34
Analysts Are Bullish on Top Healthcare Stocks: Harmony Biosciences Holdings (HRMY), Recursion Pharmaceuticals (RXRX)
TipRanks · 04/09 10:30
Weekly Report: what happened at HRMY last week (0401-0405)?
Weekly Report · 04/08 10:19
HARMONY BIOSCIENCES INITIATES GLOBAL PHASE 3 REGISTRATIONAL TRIAL (TEMPO STUDY) OF PITOLISANT IN PATIENTS WITH PRADER-WILLI SYNDROME
Reuters · 04/03 12:05
Weekly Report: what happened at HRMY last week (0325-0329)?
Weekly Report · 04/01 10:18
More
Webull provides a variety of real-time HRMY stock news. You can receive the latest news about Harmony Biosciences Holdings, Inc. through multiple platforms. This information may help you make smarter investment decisions.
About HRMY
Harmony Biosciences Holdings, Inc. is a commercial-stage pharmaceutical company. The Company is focused on developing and commercializing therapies for patients living with rare neurological diseases as well as patients living with other neurological diseases who have unmet medical needs. Its product, WAKIX (pitolisant), is a first-in-class molecule with a novel mechanism of action (MOA) designed to enhance histamine signaling in the brain by binding to H3 receptors. Its WAKIX is developed for the treatment of excessive daytime sleepiness (EDS) in adult patients with narcolepsy and treatment of cataplexy in adult patients with narcolepsy. Its narcolepsy treatment works primarily through histamine, a wake-promoting neurotransmitter. It also provides HBS-102, an investigational compound, which is a melanin-concentrating hormone (MCH) receptor 1 (MCHR1) antagonist that targets MCH neurons in the brain. It also develops ZYN002, a pharmaceutically manufactured synthetic cannabidiol.